No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IXHL Incannex Healthcare
- 2.240
- -0.010-0.44%
Close Jul 22 16:00 ET
- 2.140
- -0.100-4.46%
Post 19:48 ET
39.52MMarket Cap1.63P/E (TTM)
2.265High2.200Low15.05KVolume2.210Open2.250Pre Close33.42KTurnover0.11%Turnover RatioLossP/E (Static)17.64MShares12.68052wk High2.80P/B30.90MFloat Cap1.96052wk Low--Dividend TTM13.80MShs Float360.000Historical High--Div YieldTTM2.89%Amplitude1.960Historical Low2.220Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Incannex Healthcare Files For Offering Of 4M Common Shares Along With Warrants To Purchase Up To 4M Common Shares
Express News | Incannex Healthcare Inc Files for Offering 4 Mln Common Shares Together With Common Warrants to Purchase up to 4 Mln Common Shares - SEC Filing
Express News | Incannex Healthcare Commences Dosing In Phase 2/3 Clinical Trial Assessing IHL-42X In Obstructive Sleep Apnea
Express News | Patient Dosing Commenced in Reposa Phase 2/3 Clinical Trial Protocol to Assess Ihl-42X Drug in Patients With Obstructive Sleep Apnea
Why Incannex Healthcare's (NASDAQ:IXHL) Earnings Are Weaker Than They Seem
Investors were disappointed with Incannex Healthcare Inc.'s (NASDAQ:IXHL) recent earnings release. We did some digging and found some underlying numbers that are worrying. NasdaqGM:IXHL Earnings a
10-Q: Quarterly report
Comments
$Incannex Healthcare(IXHL.US$ Incannex Healthcare Commences Dosing In Phase 2/3 Clinical Trial Assessing IHL-42X In Obstructive Sleep Apnea
$Incannex Healthcare(IXHL.US$
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
1
For Incannex, this teleconference was a platform to engage with various divisions of the FDA.
Incannex Healthcare Inc. (Nasdaq: IXHL), biotechnology company, specializing in cannabinoid and psychedelic medicine, marked a significant milestone on May 7, 2024, with the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA). This crucial step forward perta...
Incannex Healthcare Inc. (Nasdaq: IXHL), biotechnology company, specializing in cannabinoid and psychedelic medicine, marked a significant milestone on May 7, 2024, with the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA). This crucial step forward perta...
$Incannex Healthcare(IXHL.US$ Reuters· 1 min ago
Incannex Complete Successful Pre-Ind Meeting With the FDA for Cannquit-O for Treatment of Opioid Use Disorder
Incannex Complete Successful Pre-Ind Meeting With the FDA for Cannquit-O for Treatment of Opioid Use Disorder
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg